Book contents
- Neuromuscular Disease: A Case-Based Approach
- Neuromuscular Disease
- Copyright page
- Contents
- Contributors
- Foreword
- Preface to 2nd Edition
- Part I Evaluation and Treatment of Patients with a Neuromuscular Disorder
- Part II Neuromuscular Cases
- Disorders of the Anterior Horn Cell
- Peripheral Neuropathies
- Case 9 Guillain–Barré Syndrome (GBS) and Miller–Fisher Syndrome (MFS)
- Case 10 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Case 11 IgM Anti-MAG Polyneuropathy
- Case 12 Polyneuropathy, Organomegaly, Endocrine Manifestations, Monoclonal Protein, and Skin Changes (POEMS) Syndrome
- Case 13 Vasculitic Neuropathy
- Case 14 Small-Fibre Neuropathy (SFN)
- Case 15 Sensory Neuronopathy (SNN, Ganglionopathy)
- Case 16 Wartenberg Migrant Sensory Neuropathy
- Case 17 Multifocal Motor Neuropathy (MMN)
- Case 18 Peripheral Nerve Hyperexcitability Syndromes: Morvan Syndrome
- Case 19 Idiopathic Brachial Plexus Neuropathy, Neuralgic Amyotrophy (NA)
- Case 20 Diabetic Neuropathy
- Case 21 Alcoholic Polyneuropathy
- Case 22 Chronic Idiopathic Axonal Polyneuropathy (CIAP)
- Case 23 Critical Illness Polyneuropathy and Myopathy (CIPM)
- Case 24 Drug-Induced Polyneuropathies: Amiodarone Polyneuropathy
- Case 25 Lyme Radiculopathy
- Case 26 Leprosy
- Case 27 Charcot–Marie–Tooth Disease (CMT) Type 1A/Hereditary Neuropathy with Liability for Pressure Palsies (HNPP)
- Case 28 Charcot–Marie–Tooth Disease (CMT) Type 2 A and Type 2B
- Case 29 Hereditary Sensory and Autonomic Neuropathy (HSAN) Type 4
- Case 30 Hereditary Transthyretin (TTR) Amyloidosis
- Disorders of the Neuromuscular Junction
- Myopathies
- Video legends
- Index
- References
Case 12 - Polyneuropathy, Organomegaly, Endocrine Manifestations, Monoclonal Protein, and Skin Changes (POEMS) Syndrome
from Peripheral Neuropathies
Published online by Cambridge University Press: 29 November 2024
Book contents
- Neuromuscular Disease: A Case-Based Approach
- Neuromuscular Disease
- Copyright page
- Contents
- Contributors
- Foreword
- Preface to 2nd Edition
- Part I Evaluation and Treatment of Patients with a Neuromuscular Disorder
- Part II Neuromuscular Cases
- Disorders of the Anterior Horn Cell
- Peripheral Neuropathies
- Case 9 Guillain–Barré Syndrome (GBS) and Miller–Fisher Syndrome (MFS)
- Case 10 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Case 11 IgM Anti-MAG Polyneuropathy
- Case 12 Polyneuropathy, Organomegaly, Endocrine Manifestations, Monoclonal Protein, and Skin Changes (POEMS) Syndrome
- Case 13 Vasculitic Neuropathy
- Case 14 Small-Fibre Neuropathy (SFN)
- Case 15 Sensory Neuronopathy (SNN, Ganglionopathy)
- Case 16 Wartenberg Migrant Sensory Neuropathy
- Case 17 Multifocal Motor Neuropathy (MMN)
- Case 18 Peripheral Nerve Hyperexcitability Syndromes: Morvan Syndrome
- Case 19 Idiopathic Brachial Plexus Neuropathy, Neuralgic Amyotrophy (NA)
- Case 20 Diabetic Neuropathy
- Case 21 Alcoholic Polyneuropathy
- Case 22 Chronic Idiopathic Axonal Polyneuropathy (CIAP)
- Case 23 Critical Illness Polyneuropathy and Myopathy (CIPM)
- Case 24 Drug-Induced Polyneuropathies: Amiodarone Polyneuropathy
- Case 25 Lyme Radiculopathy
- Case 26 Leprosy
- Case 27 Charcot–Marie–Tooth Disease (CMT) Type 1A/Hereditary Neuropathy with Liability for Pressure Palsies (HNPP)
- Case 28 Charcot–Marie–Tooth Disease (CMT) Type 2 A and Type 2B
- Case 29 Hereditary Sensory and Autonomic Neuropathy (HSAN) Type 4
- Case 30 Hereditary Transthyretin (TTR) Amyloidosis
- Disorders of the Neuromuscular Junction
- Myopathies
- Video legends
- Index
- References
Summary
A 49-year-old man noticed a diminished sensation in his feet. Two months later, climbing stairs became difficult due to proximal muscle weakness of his legs. Over the next three months, sensory disturbances and both proximal and distal weakness progressed in arms and legs requiring the use of a walker or a wheelchair. Besides COPD, he was previously in a healthy condition. Based upon ancillary investigations, he was initially diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP), had received a course of intravenous Ig (IVIg), and was subsequently treated with high-dose corticosteroids (60 mg/day). He did not smoke or use drugs such as nitric oxide.
Keywords
- Type
- Chapter
- Information
- Neuromuscular DiseaseA Case-Based Approach, pp. 104 - 106Publisher: Cambridge University PressPrint publication year: 2024
References
Suggested Reading
Bou Zerdan, M, George, TI, Bunting, ST, Chaulagain, CP. Recent advances in the treatment and supportive care of POEMS syndrome. J Clin Med 2022;11(23):7011. doi: 10.3390/jcm11237011. PMID: 36498588; PMCID: PMC9741379.CrossRefGoogle ScholarPubMed
Dispenzieri, A. POEMS syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol 2019;94(7):812–827. doi: 10.1002/ajh.25495. Epub 2019 May 23. PMID: 31012139.CrossRefGoogle ScholarPubMed
D’Sa, S, Khwaja, J, Keddie, S, et al. Comprehensive diagnosis and management of POEMS syndrome. Hemasphere 2022;6(11):e796. doi: 10.1097/HS9.0000000000000796. PMID: 36340912; PMCID: PMC9624442.CrossRefGoogle ScholarPubMed
Khouri, J, Nakashima, M, Wong, S. Update on the diagnosis and treatment of POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome: a review. JAMA Oncol 2021;7(9):1383–1391. doi: 10.1001/jamaoncol.2021.0586. PMID: 34081097.CrossRefGoogle ScholarPubMed
Kim, YR. Update on the POEMS syndrome. Blood Res 2022;57(S1):27–31. doi: 10.5045/br.2022.2022001. PMID: 35483922; PMCID: PMC9057663.CrossRefGoogle ScholarPubMed